Germline genetic testing and clinical consequences for patients and relatives in onco-urology

Live from the studio: Thematic Session 08

Saturday 10 July 13:15 - 14:15	and the predicted risks	Virtual Room 2 P. Albers, Düsseldorf (DE) R.A. Eeles, London (GB) B. Faltas, New York (US) F.C. Hamdy, Oxford (GB) A. Stenzl, Tübingen (DE) nerging tool for risk consultations. However, the test reliability differ tremendously. This session will highlight the newest and how to integrate genetic tests in clinical routine.
13:15 - 13:35	What urologists need to know about germline mutations and prostate cancer management	
13:15 - 13:20	State-of-the-art lecture Germline mutations and prostate cancer management R.A. Eeles, London (GB)	
13:20 - 13:25	Clinical case presentation Germline mutations and prostate cancer management N. Fossati, Milan (IT)	
13:25 - 13:35	Discussion <i>Moderator Discussants</i>	F.C. Hamdy, Oxford (GB) R.A. Eeles, London (GB) N. Fossati, Milan (IT)
13:35 - 13:55	What urologists need to know about germline mutations and kidney cancer management	
13:35 - 13:40	State-of-the-art lecture U. Capitanio, Milan (IT)	Germline mutations and kidney cancer management
13:40 - 13:45	Clinical case presentation Germline mutations and kidney cancer management M.C. Mir Maresma, Valencia (ES)	
13:45 - 13:55	Discussion Discussants Moderator	U. Capitanio, Milan (IT) M.C. Mir Maresma, Valencia (ES) W.M. Linehan, Bethesda (US)
13:55 - 14:15	What urologists need to know about germline mutations and urothelial cancer management	
13:55 - 14:00	State-of-the-art lecture Germline mutations and urothelial cancer management B. Faltas, New York (US)	
14:00 - 14:05	Clinical case presentation Germline mutations and urothelial cancer management G. Niegisch, Düsseldorf (DE)	
14:05 - 14:15	Discussion <i>Moderator Discussants</i>	P. Black, Vancouver (CA) B. Faltas, New York (US) G. Niegisch, Düsseldorf (DE)